Medline (NASDAQ:MDLN) Research Coverage Started at Wells Fargo & Company

Wells Fargo & Company assumed coverage on shares of Medline (NASDAQ:MDLN) in a research report sent to investors on Monday morning, MarketBeat.com reports. The brokerage issued an equal weight rating and a $42.00 price objective on the stock.

MDLN has been the subject of several other research reports. Deutsche Bank Aktiengesellschaft started coverage on shares of Medline in a research note on Monday. They set a “hold” rating and a $40.00 target price for the company. The Goldman Sachs Group initiated coverage on Medline in a research note on Monday. They issued a “buy” rating and a $49.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on Medline in a research report on Monday. They set an “overweight” rating and a $50.00 target price on the stock. Wall Street Zen upgraded Medline to a “hold” rating in a research report on Saturday, January 10th. Finally, Robert W. Baird started coverage on Medline in a research note on Monday. They set an “outperform” rating and a $48.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $46.70.

Medline Stock Performance

Shares of MDLN stock opened at $43.41 on Monday. Medline has a 1 year low of $34.89 and a 1 year high of $45.50.

Insider Activity at Medline

In other news, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of Medline stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the completion of the sale, the insider directly owned 4,806,160 shares in the company, valued at $136,350,759.20. The trade was a 55.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Charles N. Mills acquired 2,579,310 shares of the business’s stock in a transaction dated Thursday, December 18th. The stock was purchased at an average cost of $29.00 per share, with a total value of $74,799,990.00. Following the transaction, the director owned 2,441,379 shares of the company’s stock, valued at approximately $70,799,991. The trade was a -1,870.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Trending Headlines about Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Several major brokers initiated bullish coverage or set high price targets (Truist $52, Evercore $50, BTIG $50, Goldman $49, Sanford Bernstein $49, UBS $48, RBC $47, BMO $45, Leerink/Baird strong-buy). Those reports signal upward earnings/market-share expectations and provide concrete upside targets for investors, supporting the rally. Analyst Coverage & Targets (Benzinga)
• Neutral Sentiment: Widespread coverage initiations across big banks (Deutsche Bank, Jefferies, Wells Fargo, JPMorgan, Citigroup, Barclays, Mizuho, TD Cowen, Wolfe Research, Rothschild/Redburn, BNP Paribas Exane) increase the stock’s visibility and institutional research footprint—likely to lift liquidity and investor interest over time but not an immediate fundamental change on its own. Coverage Initiations (AmericanBankingNews)
• Neutral Sentiment: Press coverage highlighting a strong market debut and “aging dividend” thematic interest has helped momentum traders and retail investors take notice; this amplifies the technical lift but is not new company-specific fundamental news. Market Debut Coverage (NAI500)
• Negative Sentiment: Not all firms are uniformly bullish—BNP Paribas and Rothschild/Redb issued “hold” ratings for now. These more cautious views could cap near-term upside if other analysts temper forecasts or if results miss elevated expectations. Hold Ratings (Zacks)

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.